[Selenium in blood serum and in tumors of patients with benign and malignant bone neoplasms].

The content of selenium in the serum and bones was compared in persons having no neoplasms and in patients with malignant and benign bone tumors. The mean level of selenium in the healthy femoral bone was 81 micrograms/kg, with more predominant accumulation in the epiphysis than in the metaphysis and diaphysis and with higher concentrations in the periosteum than in the cambial layer. The normal mean bone/serum selenium ratio was 0.74. This index varied 0.8 to 5.1 in patients with benign tumors and 2.3 to 10.0 in those with malignant tumors. Benign tumors were characterized by significant multiple variations of tumor selenium levels depending on the type of an abnormality with maximally observed values in giant-cell tumor. In patients with various osteosarcomas, the mean selenium content was decreased to 71% in the serum and increased up to 300% in the tumor. The examination of the impact of the type of non-adjuvant therapy on serum selenium levels in patients with bone tumors indicated a negative selenium effect in the application of radiation therapy and a positive selenium effect in the transfusion of bone marrow suspension and in the use of platidium or SAR-regimen therapy.